Lifeward Ltd. · NASDAQ:LFWD
Lifeward — ReWalk Robotics — IPO Roadshow (January 2020)
28 slides from Lifeward's IPO roadshow presentation, Jan 30, 2020
Slide 1: Human and Robotic Intersection Take the Next Step
Human and Robotic Intersection Take the Next Step 1 January 2020 ReWalk Confidential. © 2018 ReWalk Robotics, Inc. Markets spring into being when economic actors shift resources to that firm's solution Issuer Free Writing Prospectus dated January 30, 2020 Filed Pursuant to Rule 433 Registration Stat
Slide 2: Disclaimer
Disclaimer ▪ This presentation contains statistical data that were obtained from industry publications and reports generated by third parties. Although ReWalk believes that the publications and reports are reliable, it has not independently verified this statistical data. ▪ The trademarks included h
Slide 3: Free Writing Prospectus
Free Writing Prospectus ReWalk Robotics Ltd . (the “Company” or “ReWalk”) has filed a registration statement on Form S - 1 (File No . 333 - 235932 ), including a preliminary prospectus (the “Preliminary Prospectus”), with the Securities and Exchange Commission (the “SEC”) for the offering to which t
Slide 4: Our Mission
Fundamentally change the Quality of Life for individuals with disability through the creation and development of market leading robotic technologies Our Mission 4
Slide 5: 2020 Market and Company Thresholds
2020 Market and Company Thresholds • Completed and pending German contracts establish the implementation procedures for coverage for the majority of German Spinal Cord Injury population • US Veterans Administration 160 patients randomized study 2 accrual complete; supports reimbursement and access t
Slide 6: Current Product Overview
ReWalk™ Rigid Exoskeleton » Assists individuals with Spinal Cord Injury (“SCI”) to stand and walk » FDA & CE mark clearance; 6 th generation - ~572 systems placed to date; 5 years of use » Reimbursement: VA, Germany, Italy, different payor on a case by case » First mover advantage with extensive IP
Slide 7: Target Market Applications for Technologies
Target Market Applications for Technologies ___________________________ 1. https://www.nscisc.uab.edu/Public/Facts%20and%20Figures%202019%20 - %20Final.pdf 2. https://www.heart.org/idc/groups/heart - public/@wcm/@hcm/@ml/documents/downloadable/ucm_455522.pdf 3. Primary + Skilled Nursing facility fig
Slide 8: Spinal Cord Injury Impact: Need for Technical Solutions
Spinal Cord Injury Impact: Need for Technical Solutions ___________________________ 1. Source: https://www.nscisc.uab.edu/Public/Facts%20and%20Figures%202019%20 - %20Final.pdf 2. Source: https://www.nscisc.uab.edu/public/2016%20Annual%20Report%20 - %20Complete%20Public%20Version.pdf Wheelchair confi
Slide 9: ReWalk Personal 6.0 System – How it Works
ReWalk Personal 6.0 System – How it Works Patented tilt - sensor technology that provides more natural gait and functional walking speed 9
Slide 10: Spinal Cord Injury: ReWalk Market Creation Status Today
Spinal Cord Injury: ReWalk Market Creation Status 10 Today FDA CE Creation & Product Refinement VA Study 4 Yr 160 randomized Full Scale German Coverage Contracts VA Data Published 198 Case by Case Approvals to Date German Code 572 units placed to Date Achieving Market Access CMS Determination Develo
Slide 11: ReWalk Exo-Suit for Stroke, Multiple Sclerosis, Parkinson's
11 ReWalk Confidential. © 2018 ReWalk Robotics, Inc. Exo - Suit for Stroke, Multiple Sclerosis, Parkinson’s
Slide 12: ReStore – Shaping the Future of Stroke Therapy
Exo - suits: ReStore – Shaping the Future of Stroke Therapy » Provides coordinated plantarflexion and dorsiflexion assistance to facilitate a natural gait » Rapid, automatic adaptation to patient’s gait » Versatile for “main street” clinics » Data driven » Disposable elements provides recurring reve
Slide 13: Game Changing: Paretic Propulsion
Game Changing: Paretic Propulsion Paretic Propulsion = a measure of the contribution of the affected (paretic) limb to advance the body forward during walking, in comparison to the contributions of the unaffected (nonparetic) limb . 1 Awad, Louis N et al. “Paretic Propulsion and Trailing Limb Angle
Slide 14: ReStore: How It Works Key Differentiators
ReStore: How It Works 14 Key Differentiators » Light, soft components and powered dorsi / plantar flexion facilitate natural gait pattern » Provides therapist real - time analytics and enhanced session control for optimized results » Multiple modes of function, rapid donning/ doffing and adjustment
Slide 15: Easy-to-use Therapist App
Easy - to - use Therapist App 15 » Three modes of activation » Real time adjusted assistance level » Built in test sessions » Variery of statistics to support patient progress - ▪ Assistance level , Symmetry ▪ Distance ▪ Steps ▪ Speed Session # 8/20/2018 # of steps 100 Assist 100 Brace 100 Avg. NP s
Slide 16: Highlighted Findings from Exosuit Studies
[ 1 ] Awad, Louis N . , et al . "A soft robotic exosuit improves walking in patients after stroke . " Science translational medicine 9 . 400 ( 2017 ) : eaai 9084 . [ 2 ] Awad, Louis N . , et al . "Reducing Circumduction and Hip Hiking During Hemiparetic Walking Through Targeted Assistance of the Par
Slide 17: Exo-suit Case Study
Exo - suit - Case Study 17 Porcuincula et al. “Soft Robotic Exosuits for Targeted Gait Rehabilitation After Stroke: A Case Study” American Society of Ne uro rehabilitation conference 2019. A 58 year old male with chronic stroke participated in two 2 - week training bouts separated by a 7 - week wash
Slide 18: ReStore Market: Stroke
ReStore: Market: Stroke US: 7 million stroke survivors 1 EU: 9.6 million stroke survivors 2 China: 11 million stroke survivors ⁸ US: 3.3 million 5,6 potentially eligible for ReStore system EU: 4.6 million 7 potentially eligible for ReStore system China: 5.3 million 7 US: ~ 795K 3 EU / Western Europe
Slide 19: ReStore: Position in Market
ReStore: Position in Market 19
Slide 20: ReStore: Impact On Stroke Patient
ReStore: Impact On Stroke Patient 20
Slide 21: ReStore Around the World
21 ReStore Around the World United Kingdom Helsinki California Germany
Slide 22: Path to Profitability: Multiple Products and Leveraged Distribution System
MS/ Stroke - Hip Exo - suit Stroke Home / Clinic Low Cost Exo - suit Path to Profitability: Multiple Products and Leveraged Distribution System 22 2018 2019 2020 2021 2022 • German Contracts • VA Study Results • Expanded US Coverage • Next Gen Prototypes Stroke Clinic “ReStore” - Soft Exosuit SCI -
Slide 23: Exo-Suit Home Use Device - Market Potential
Exo - Suit Home Use Device - Market Potential 23 795 145 150 500 New and Recurrent Strokes Mortality Functional Gait Impaired Gait Incidence (‘000s) U.S Yearly Stroke Incidence rate 1 » ~500K patients are discharged home with impaired gait following stroke annually – although approx. 80% of stroke s
Slide 24: Exo-Suit Hip Rehab Device - Market Potential
Exo - Suit Hip Rehab Device - Market Potential 24 ___________________________ Source: Pubmed , see “ Target Market Applications for Technologies slide” above » Hip Device functionality will potentially allow it to be a novel treatment for a variety of indications Hip Rehab Device Lumbosacral Radicul
Slide 25: Investment Highlights
Investment Highlights 25 » Market leading global exoskeleton developer with breakthrough device platforms and various vectors ▪ Sales team expanded with experienced capital equipment sales personnel as of YE 2019 ▪ Rigid ReWalk exoskeleton for Spinal Cord Injury market - • German insurance contracts
Slide 26: Key Financial and Operational Data
Key Financial and Operational Data Profit and Loss (in Thousands of $, except for units placed data) YTD Sep 2019 (Unaudited) YTD Sep 2018 (Unaudited) FY 2018 (Audited) Revenue 3,692 4,966 6,545 SCI - Units Placed 39 64 85 ReStore – Units Placed 6 - - Gross Margin % 54% 45% 43% Operating expenses (
Slide 27: Take the Next Step - Thank You!
Take the Next Step 27 www.rewalk.com Thank You!
Slide 28: Forward Looking Statements
Forward Looking Statements 28 In addition to historical information, this presentation of ReWalk Robotics Ltd . (“ReWalk, the “Company,” “we” or “us”) contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, Section 21 E of the Securities E